SVB Wealth LLC Reduces Position in Walgreens Boots Alliance, Inc. (NASDAQ:WBA)

SVB Wealth LLC reduced its holdings in Walgreens Boots Alliance, Inc. (NASDAQ:WBA) by 27.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,246 shares of the pharmacy operator’s stock after selling 14,849 shares during the period. SVB Wealth LLC’s holdings in Walgreens Boots Alliance were worth $1,025,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of WBA. Sumitomo Mitsui Trust Holdings Inc. raised its position in Walgreens Boots Alliance by 12.4% in the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,077,336 shares of the pharmacy operator’s stock valued at $80,349,000 after purchasing an additional 339,143 shares during the period. Louisiana State Employees Retirement System purchased a new position in Walgreens Boots Alliance during the fourth quarter worth about $2,924,000. Lauer Wealth LLC increased its position in shares of Walgreens Boots Alliance by 17.0% during the fourth quarter. Lauer Wealth LLC now owns 41,324 shares of the pharmacy operator’s stock valued at $1,079,000 after acquiring an additional 5,991 shares during the last quarter. Sprucegrove Investment Management Ltd. lifted its holdings in shares of Walgreens Boots Alliance by 1.3% in the 4th quarter. Sprucegrove Investment Management Ltd. now owns 398,958 shares of the pharmacy operator’s stock worth $10,417,000 after acquiring an additional 5,300 shares during the last quarter. Finally, ORG Partners LLC boosted its position in shares of Walgreens Boots Alliance by 352.1% during the 4th quarter. ORG Partners LLC now owns 2,057 shares of the pharmacy operator’s stock worth $54,000 after purchasing an additional 1,602 shares during the period. 58.59% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Inderpal S. Bhandari purchased 3,000 shares of the business’s stock in a transaction that occurred on Thursday, April 11th. The shares were purchased at an average cost of $18.05 per share, for a total transaction of $54,150.00. Following the purchase, the director now directly owns 3,000 shares of the company’s stock, valued at $54,150. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CFO Manmohan Mahajan acquired 6,000 shares of the firm’s stock in a transaction dated Tuesday, April 2nd. The stock was acquired at an average cost of $19.38 per share, with a total value of $116,280.00. Following the completion of the acquisition, the chief financial officer now owns 166,969 shares of the company’s stock, valued at $3,235,859.22. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Inderpal S. Bhandari bought 3,000 shares of the business’s stock in a transaction dated Thursday, April 11th. The stock was acquired at an average cost of $18.05 per share, for a total transaction of $54,150.00. Following the completion of the acquisition, the director now directly owns 3,000 shares in the company, valued at $54,150. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 13,456 shares of company stock worth $270,423. Corporate insiders own 17.40% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on WBA shares. TD Cowen dropped their price objective on Walgreens Boots Alliance from $37.00 to $35.00 and set a “buy” rating for the company in a research note on Wednesday, April 3rd. HSBC reiterated a “reduce” rating and set a $20.00 price target (down from $27.00) on shares of Walgreens Boots Alliance in a research note on Tuesday, February 20th. Morgan Stanley lowered their price objective on shares of Walgreens Boots Alliance from $21.00 to $20.00 and set an “underweight” rating for the company in a research note on Monday, April 1st. Truist Financial reaffirmed a “hold” rating and set a $25.00 target price on shares of Walgreens Boots Alliance in a research note on Monday, April 1st. Finally, TheStreet raised shares of Walgreens Boots Alliance from a “d+” rating to a “c-” rating in a research report on Monday, January 8th. Four investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $24.36.

Walgreens Boots Alliance Stock Down 0.2 %

Walgreens Boots Alliance stock opened at $17.59 on Friday. The stock’s fifty day moving average is $20.50 and its two-hundred day moving average is $21.95. Walgreens Boots Alliance, Inc. has a 1-year low of $17.51 and a 1-year high of $36.14. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.32 and a current ratio of 0.66.

Walgreens Boots Alliance (NASDAQ:WBA) last posted its earnings results on Thursday, March 28th. The pharmacy operator reported $1.20 earnings per share for the quarter, topping the consensus estimate of $0.82 by $0.38. The firm had revenue of $37.05 billion during the quarter, compared to analysts’ expectations of $35.86 billion. Walgreens Boots Alliance had a positive return on equity of 12.11% and a negative net margin of 4.18%. The firm’s revenue was up 6.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.16 earnings per share. On average, equities research analysts anticipate that Walgreens Boots Alliance, Inc. will post 3.23 EPS for the current fiscal year.

Walgreens Boots Alliance Profile

Walgreens Boots Alliance, Inc operates as a healthcare, pharmacy, and retail company in the United States, the United Kingdom, Germany, and internationally. It operates through three segments: U.S. Retail Pharmacy, International, and U.S. Healthcare. The U.S. Retail Pharmacy segment engages in operation of the retail drugstores, health and wellness services, specialty, and home delivery pharmacy services, which offers health and wellness, beauty, personal care and consumables, and general merchandise.